Although HER2-targeted therapies in combination with chemotherapy have significantly improved the treatment and survival of HER2+ breast cancer patients [3–10], in clinical practice HER2+ breast cancer patients are not homogeneous in terms of disease progression, prognosis and response to therapeutic regimens [11]. This evidence concerns the gene ERBB2 and breast carcinoma.